BARDA Director Gary Disbrow (Graeme Jennings/Pool via AP Images)
June 28, 2024 01:50 PM EDTUpdated 03:38 PM
Pharma
Coronavirus

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Max Bayer

Pharma Reporter

In 2023, Vaxart halt­ed work on its oral vac­cine for Covid-19, and didn’t even have enough mon­ey to fin­ish 2024.

Now, the US gov­ern­ment is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

A service from the Financial Times